Aminoglycosides Flashcards

1
Q

what are the common aminoglycosides

A

Gentamicin
Tobramycin
amikacin
streptomycin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

how do aminoglycosides work

A

Irreversibly bind to 30S ribosomal subunit of susceptible bacteria resulting in inhibition of protein synthesis
Cell entry is oxygen-dependent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

mechanisms of resistance to aminoglycosides

A

• Synthesis of AG modifying enzymes
Plasmid-mediated
>50 AG altering enzymes
Cause acetyl-, adenyl-, or phosphorylation
these changes usually result in altered uptake or binding
• Altered AG uptake
Loss of porin channel
Efflux pump
• Change in ribosomal binding site/target modification

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

gentamicin spectrum of activity

A
Gram-negative
E. coli
K. pneumoniae
Proteus
Citrobacter
Enterobacter
Morganella
Serratia
Pseudomonas
Gram-positive
Enterococcus
S. aureus
Viridans Streptococcus
S. pyogenes

very good gram negative, has the best synergy for enterococcus treatment

least pseudomonas activity of the aminoglycosides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what would you use to treat enterococcus (gram +)

A

gentamicin + ampicillin (or another pcn or vancomycin)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Spectrum of Activity 
Tobramycin

A

Gram-negative

Similar to gentamicin BUT
More active against Pseudomonas**

Slightly less active against other gram-negatives

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Spectrum of Activity
 Amikacin

A

Gram-negative
Generally, most active against nosocomial gram-negatives (except vs tobra for Pseudomonas, most of the time)

Mycobacterial
M. tuberculosis
Atypical mycobacteria

Others
Nocardia

used as a broad spectrum 2nd choice empiric therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what to use when treating Pseudomonas with an aminoglycoside

A

Tobramycin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Spectrum of Activity 
Streptomycin

A

Gram-positive
Enterococcus

Mycobacterial
M. tuberculosis
Less atypical mycobacteria than amikacin

mainly used for Enterococcus if gentamicin cannot be used

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

aminoglycosides and synergy

A
  • Synergy between cell wall active agents and AGs

* Likely due to enhanced AG uptake

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

aminoglycoside distribution

A
  • Low in CSF, bronchial secretions, bile (30%), vitreous humor (40%)
  • high/good Pleural, pericardial, ascitic, and synovial fluid ~50% of serum
  • High in urine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

aminoglycoside elimination

A

99% renally eliminated (urine conc ~ 50-100x serum conc)
30-40% removed by hemodialysis
Linear PK - doubling the dose doubles the concentration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Pharmacodynamics

A
  • Concentration-dependent killing

* PK/PD parameter: peak/MIC (goal ≥ 8 – 10) higher = more optimal efficacy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Postantibiotic Effect

A

Persistent suppression of bacterial growth after drug concentration falls below the MIC of targeted organism

wide range of aminoglycosides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Postantibiotic Effect is impacted by

A

Organism
Drug concentration
Duration of drug exposure
Antimicrobial combinations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Dosing 
Gentamicin and Tobramycin for a gram negative infection

A

Traditional : doses give 3x a day or every 8 hours - keeps a more constant low level of drug present

extended interval (once a day) dosing : give one large dose per day - higher peak lower trough

17
Q

Dosing 
Amikacin for gram negative

A

doses are 2-3x what you would give for gentamicin or tobramycin.

may use traditional or extended interval

18
Q

Dosing
 for Gram-positive infections

A

use either gentamicin or streptomycin, gram positive bacteria are killed time dependently therefore multiple smaller and more frequent doses are given

19
Q

Dosing 
Mycobacterial infections

A

Amikacin/streptomycin given in high doses (higher than for gram negative) once a day or less but over a much longer time period (months)

20
Q

Traditional vs. Extended-Interval Dosing

A
Traditional dosing (MDD)
Approximately same daily dose given every 8 to 12 hours

Extended-interval dosing (ODA)
One large dose given at an interval no less than every 24 hours

21
Q

Rationale for Extended-Interval Dosing

A
Concentration-dependent bactericidal activity
Post-antibiotic effect (PAE)
Adaptive resistance - may become less resistant during off time
Minimize toxicities
Nephrotoxicity
Ototoxicity
Cost savings
Efficacy
22
Q

Nephrotoxicity of aminoglycoids

A
  • Related to intracellular accumulation of drug in the renal cortex
  • Uptake of AGs into proximal tubule cells is saturable at clinically achieved concentrations
  • Animal studies have shown that continuous infusion AG results in higher renal cortical concentrations compared with a single daily injection regimen – thought to be due to the amount accumulated over time not peak concentration
  • REVERSIBLE
23
Q

ways to decrease nephrotoxicity

A

give higher doses less frequently

make sure to get a low trough level to give kidney time without drug

24
Q

Ototoxicity with aminoglycoids

A
  • Uptake of AGs into different inner ear tissues does not correlate with the degree of ototoxicity
  • Sparse data for risk of ototoxicity based on dosing regimen
  • does not seem to correlate with any dosing perimeter
25
Q

how does extended interval dosing save money

A

Decreased pharmacy preparation time

Decreased nursing administration time

Potentially decreased drug concentration monitoring

26
Q

Clinical Uses of aminoglycoids for gram negative infections

A
  • gent, tobra, amikacin
  • In combination with beta-lactams to treat resistant and/or serious infections
  • Empiric treatment of sepsis, especially from a urinary source
  • Bloodstream, intraabdominal infections, skin/soft tissue infections
  • Need to use high dose if giving for pneumonia
  • Rarely used as monotherapy
27
Q

clinical uses of aminoglycoids for gram positive infections

A
  • mostly gent, some strepto
  • In combination with beta-lactams (ampicillin or nafcillin) or vancomycin for severe infections (enterococcal or staphylococcal endocarditis)
  • High peak concentrations are NOT necessary so low dose is sufficient
28
Q

aminoglycoid use for mycobacteria infections

A
  • amikacin, streptomycin

* In combination with multiple antimycobacterial agents

29
Q

risk factors for nephrotoxicities

A

prolonged/repeditive use, *elevated trough concentrations, prolonged therapy, underlying renal insufficiency, advanced age, hypovolemia, concomitant nephrotoxins

Gent > tobra > amik > strepto

30
Q

Ototoxicity risk factors

A

Usually irreversible (may appear after the end of treatment)

Risk factors: increased age, prolonged AG course, ?increased serum concentrations, ?genetic factors – not as well understood

31
Q

best way to enhance efficacy and minimize toxicity

A

get in and get out

optimize the Peak/MIC ratio by giving high but infrequent doses